Cargando…

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency

BACKGROUND: Acute exacerbations of COPD (AECOPD) have unclear impacts on emphysema measurement using computed tomography (CT)-derived 15th percentile lung density (PD15). The aim of this study was to assess the influence of AECOPD on PD15 lung density in α(1)-antitrypsin deficiency. METHODS: In a po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strange, Charlie, McElvaney, N. Gerard, Vogelmeier, Claus F., Marin-Galiano, Marcos, Buch-Haensel, Michaela, Zhang, Xiang, Chen, Younan, Vit, Oliver, Wencker, Marion, Chapman, Kenneth R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009703/ https://www.ncbi.nlm.nih.gov/pubmed/36923570 http://dx.doi.org/10.1183/23120541.00457-2022

Ejemplares similares

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
por: Greulich, Timm, et al.
Publicado: (2016)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Imaging in alpha-1 antitrypsin deficiency: a window into the disease
por: Huang, Yuh-Chin Tony, et al.
Publicado: (2021)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
por: O'Brien, Michael E, et al.
Publicado: (2020)

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry
por: Bernhard, Nikolas, et al.
Publicado: (2017)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life
por: Beiko, Tatsiana, et al.
Publicado: (2019)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
por: Miravitlles, Marc, et al.
Publicado: (2022)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
por: O’Shea, Orlagh, et al.
Publicado: (2023)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study
por: Stocks, James M, et al.
Publicado: (2010)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
por: McGee, Dawn, et al.
Publicado: (2010)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
por: McElvaney, Oliver J., et al.
Publicado: (2022)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Detection of alpha-1 antitrypsin deficiency: the past, present and future
por: Brantly, Mark, et al.
Publicado: (2020)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency
por: Fee, Laura T., et al.
Publicado: (2021)

Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB
por: Hassan, Tidi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q5rni1gek3d8cdgp9m4aqv9c7o